Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing the Impact of Aminophylline in the Reversal of Complete Heart Block Secondary to Inferior Wall MI in Atropine Resistant Patients: An Open Label Non-randomized Clinical Trial

NCT05666219 is registered in ClinicalTrials.gov with National Institute of Cardiovascular Diseases, Pakistan as lead sponsor.

NCT NCT05666219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05666219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing the Impact of Aminophylline in the Reversal of Complete Heart Block Secondary to Inferior Wall MI in Atropine Resistant Patients: An Open Label Non-randomized Clinical Trial
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan
Phase
Phase 4
Overall status
Withdrawn
Start date
December 19, 2022
Completion date
January 17, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

complete heart block, inferior wall myocardial infarction